Literature DB >> 1386864

Expression of complement components of the alternative pathway by glioma cell lines.

P Gasque1, N Julen, A M Ischenko, C Picot, C Mauger, C Chauzy, J Ripoche, M Fontaine.   

Abstract

Glioma cell lines express proteins of the complement alternative pathway, namely C3, factor B, factor H, and factor I. Secretion of these proteins was shown by a sensitive and specific ELISA. C3 and factor H were rapidly secreted by glioma cell line CB193 and reached a concentration of 140 ng/ml/10(6) cells after 72 h of culture. Factor B and factor I were secreted at a lower rate and reached concentrations of 25 and 15 ng/ml/10(6) cells, respectively. Western blot and immunoprecipitation experiments showed that secreted proteins were identical to the corresponding plasma proteins. For factor H, besides the well known 150-kDa species, an additional polypeptide of 45 kDa with factor H immunoreactivity was observed. This species corresponded to the N-terminal truncated form found in plasma. In preliminary experiments, we observed control of these syntheses by cytokines. IL-1 beta significantly increased C3 secretion, with no effect on factor H. Secretion of factor H was enhanced by IFN-gamma. These results show that a glioma cell line could be a useful tool to study complement biosynthesis by glial cells in humans.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386864

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

Review 1.  Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.

Authors:  Philippe Gasque; Jim W Neal; Sim K Singhrao; Eamon P McGreal; Yann D Dean; Beek Johan Van; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

2.  Rat complement factor I: molecular cloning, sequencing and expression in tissues and isolated cells.

Authors:  G Schlaf; E Rothermel; M Oppermann; H L Schieferdecker; K Jungermann; O Götze
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

3.  c-Jun and c-Fos regulate the complement factor H promoter in murine astrocytes.

Authors:  Laura A Fraczek; Carol B Martin; Brian K Martin
Journal:  Mol Immunol       Date:  2011-09-14       Impact factor: 4.407

4.  Complement factor I promotes progression of cutaneous squamous cell carcinoma.

Authors:  Pilvi Riihilä; Liisa Nissinen; Mehdi Farshchian; Atte Kivisaari; Risto Ala-Aho; Markku Kallajoki; Reidar Grénman; Seppo Meri; Sirkku Peltonen; Juha Peltonen; Veli-Matti Kähäri
Journal:  J Invest Dermatol       Date:  2014-09-03       Impact factor: 8.551

5.  Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis.

Authors:  S K Singhrao; J W Neal; N K Rushmere; B P Morgan; P Gasque
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

6.  Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.

Authors:  A Mäenpää; S Junnikkala; J Hakulinen; T Timonen; S Meri
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  The role of the complement system and the activation fragment C5a in the central nervous system.

Authors:  Trent M Woodruff; Rahasson R Ager; Andrea J Tenner; Peter G Noakes; Stephen M Taylor
Journal:  Neuromolecular Med       Date:  2009-09-11       Impact factor: 3.843

Review 8.  Drivers and regulators of humoral innate immune responses to infection and cancer.

Authors:  Deepak Kumar; Yeni Romero; Kaitlynn N Schuck; Haley Smalley; Bibek Subedi; Sherry D Fleming
Journal:  Mol Immunol       Date:  2020-03-18       Impact factor: 4.407

9.  Regulation of complement component C3 in astrocytes by IL-1beta and morphine.

Authors:  Jeffrey Maranto; Jay Rappaport; Prasun K Datta
Journal:  J Neuroimmune Pharmacol       Date:  2007-11-14       Impact factor: 4.147

10.  Implication of complement system and its regulators in Alzheimer's disease.

Authors:  Martin V Kolev; Marieta M Ruseva; Claire L Harris; B Paul Morgan; Rossen M Donev
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.